ingenol-dibenzoate has been researched along with Disease-Models--Animal* in 2 studies
2 other study(ies) available for ingenol-dibenzoate and Disease-Models--Animal
Article | Year |
---|---|
Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses.
Although ingenol 3,20-dibenzoate (IDB) is known as a selective novel protein kinase C (PKC) agonist, its biologic actions and underlying mechanisms remain incompletely understood. In this study, we identified IDB as a proliferative agent for an erythropoietin (EPO)-dependent cell line, UT-7/EPO, through the screening of a natural compound library. To clarify the underlying mechanism of IDB's EPO-like activities, we thoroughly analyzed the mutual relation between EPO and IDB in terms of in vitro and in vivo activities, signaling molecules, and a cellular receptor. IDB substantially induced the proliferation of UT-7/EPO cells, but not as much as EPO. IDB also lessened the anemia induced by 5-fluorouracil in an in vivo mouse model. Interestingly, IDB showed a synergistic effect on EPO at low concentration, but an antagonistic effect at higher concentration. Physical interaction and activation of PKCs by IDB- and EPO-competitive binding of IDB to EPO receptor (EPOR) explain these synergistic and antagonistic activities, respectively. Importantly, we addressed IDB's mechanism of action by demonstrating the direct binding of IDB to PKCs, and by identifying EPOR as a novel molecular target of IDB. Based on these dual targeting properties, IDB holds promise as a new small molecule modulator of EPO-related pathologic conditions. Topics: Anemia; Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Erythropoietin; Humans; Mice, Inbred C57BL; Mutation; Protein Kinase C; Receptors, Erythropoietin; Signal Transduction | 2015 |
Inflammation and inflammatory agents activate protein kinase C epsilon translocation and excite guinea-pig submucosal neurons.
Properties of enteric neurons are transformed by inflammation and protein kinase C (PKC) isoforms are involved both in long-term changes in enteric neurons, and in transducing the effects of substances released during inflammation. We investigated roles of PKCepsilon in submucosal neurons by studying translocation in response to inflammatory mediators, effects on neuron excitability, and the changes in PKCepsilon distribution in a trinitrobenzene sulphonate model of ileitis.. Immunohistochemical detection and analysis of association with membrane and cytosolic fractions, and Western blot analysis of cytosolic and particulate fractions were used to quantify translocation. Electrophysiology methods were used to measure effects on neuron excitability.. All submucosal neurons were immunoreactive for the novel PKC, PKCepsilon, and direct PKC activators, phorbol 12,13-dibutyrate, ingenol 3,20-dibenzoate, and the PKCepsilon-specific activator, transactivator of transduction-Psiepsilon receptor for activated C kinase, all caused PKCepsilon translocation from cytoplasm to surfaces of the neurons. Electrophysiologic studies showed that the stimulant of novel PKCs, ingenol (1 micromol/L), increased excitability of all neurons. Stimulation of protease-activated receptors caused PKCepsilon translocation selectively in vasoactive intestinal peptide secretomotor neurons, whereas a neurokinin 3 tachykinin receptor agonist caused translocation in neuropeptide Y and calretinin neurons. In all cases translocation was reduced significantly by a PKCepsilon-specific translocation inhibitor peptide. Increased PKCepsilon at the plasma membrane occurred in all neurons 6-7 days after an inflammatory stimulus.. Major targets for PKCepsilon include ion channels near the plasma membrane. PKCepsilon is likely to have a significant role in controlling the excitability of submucosal neurons and is probably an intermediate in causing hyperexcitability after inflammation. Topics: Action Potentials; Animals; Blotting, Western; Calbindin 2; Cell Membrane; Cytoplasm; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Guinea Pigs; Ileitis; Ileum; In Vitro Techniques; Inflammation Mediators; Kinetics; Neuropeptide Y; Oligopeptides; Peptide Fragments; Phorbol 12,13-Dibutyrate; Protein Kinase C-epsilon; Protein Transport; Receptor, PAR-2; Receptors, Neurokinin-3; S100 Calcium Binding Protein G; Signal Transduction; Submucous Plexus; Substance P; Trinitrobenzenesulfonic Acid; Trypsin; Vasoactive Intestinal Peptide | 2007 |